PACK-CXL: Corneal cross-linking in infectious keratitis

David Tabibian, Cosimo Mazzotta, Farhad Hafezi, David Tabibian, Cosimo Mazzotta, Farhad Hafezi

Abstract

Background: Corneal cross-linking (CXL) using ultraviolet light-A (UV-A) and riboflavin is a technique developed in the 1990's to treat corneal ectatic disorders such as keratoconus. It soon became the new gold standard in multiple countries around the world to halt the progression of this disorder, with good long-term outcomes in keratometry reading and visual acuity. The original Dresden treatment protocol was also later on used to stabilize iatrogenic corneal ectasia appearing after laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK). CXL efficiently strengthened the cornea but was also shown to kill most of the keratocytes within the corneal stroma, later on repopulated by those cells.

Review: Ultraviolet-light has long been known for its microbicidal effect, and thus CXL postulated to be able to sterilize the cornea from infectious pathogens. This cytotoxic effect led to the first clinical trials using CXL to treat advanced infectious melting corneal keratitis. Patients treated with this technique showed, in the majority of cases, a stabilization of the melting process and were able to avoid emergent à chaud keratoplasty. Following those primary favorable results, CXL was used to treat beginning bacterial keratitis as a first-line treatment without any adjunctive antibiotics with positive results for most patients. In order to distinguish the use of CXL for infectious keratitis treatment from its use for corneal ectatic disorders, a new term was proposed at the 9th CXL congress in Dublin to rename its use in infections as photoactivated chromophore for infectious keratitis -corneal collagen cross-linking (PACK-CXL).

Conclusion: PACK-CXL is now more frequently used to treat infections from various infectious origins. The original Dresden protocol is still used for this purpose. Careful modifications of this protocol could improve the efficiency of this technique in specific clinical situations regarding certain types of pathogens.

Keywords: CXL; Corneal cross-linking; Corneal ulcer; Infectious Keratitis; Keratoconus; PACK-CXL; Riboflavin; Ultraviolet light A.

Figures

Fig. 1
Fig. 1
Pre- and post-treatment peripheral infectious keratitis. a Anterior segment photography of a patient with early peripheral infectious keratitis (arrow). b Anterior segment OCT of the lesion. c Anterior segment photography of the same patient 7 days after PACK-CXL (9 mW/cm2 irradiance for 10 min) with resolution of the peripheral infectious keratitis (arrow). d Anterior segment OCT of the lesion at day 7 after PACK-CXL

References

    1. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135(5):620–7. doi: 10.1016/S0002-9394(02)02220-1.
    1. Wollensak G, Spoerl E, Seiler T. Stress–strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003;29(9):1780–5. doi: 10.1016/S0886-3350(03)00407-3.
    1. Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33(12):2035–40. doi: 10.1016/j.jcrs.2007.07.028.
    1. Richoz O, Mavrakanas N, Pajic B, Hafezi F. Corneal collagen cross-linking for ectasia after LASIK and photorefractive keratectomy: long-term results. Ophthalmology. 2013;120(7):1354–9. doi: 10.1016/j.ophtha.2012.12.027.
    1. Ehlers N, Hjortdal J, Nielsen K, Søndergaard A. Riboflavin-UVA treatment in the management of edema and nonhealing ulcers of the cornea. J Refract Surg. 2009;25(9):S803–6. doi: 10.3928/1081597X-20090813-08.
    1. Hafezi F, Dejica P, Majo F. Modified corneal collagen crosslinking reduces corneal oedema and diurnal visual fluctuations in Fuchs dystrophy. Br J Ophthalmol. 2010;94(5):660–1. doi: 10.1136/bjo.2009.162479.
    1. Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27(5):590–4. doi: 10.1097/ICO.0b013e318169d698.
    1. Spörl E, Huhle M, Kasper M, Seiler T. Increased rigidity of the cornea caused by intrastromal cross-linking. Ophthalmologe. 1997;94(12):902–6. doi: 10.1007/s003470050219.
    1. Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res. 1998;66(1):97–103. doi: 10.1006/exer.1997.0410.
    1. Spörl E, Schreiber J, Hellmund K, Seiler T, Knuschke P. Studies on the stabilization of the cornea in rabbits. Ophthalmologe. 2000;97(3):203–6. doi: 10.1007/s003470050515.
    1. Wollensak G, Spoerl E, Wilsch M, Seiler T. Endothelial cell damage after riboflavin-ultraviolet-A treatment in the rabbit. J Cataract Refract Surg. 2003;29(9):1786–90. doi: 10.1016/S0886-3350(03)00343-2.
    1. Hafezi F. Limitation of collagen cross-linking with hypoosmolar riboflavin solution: failure in an extremely thin cornea. Cornea. 2011;30(8):917–9. doi: 10.1097/ICO.0b013e31820143d1.
    1. Hafezi F, Mrochen M, Iseli HP, Seiler T. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Cataract Refract Surg. 2009;35(4):621–4. doi: 10.1016/j.jcrs.2008.10.060.
    1. Gkika M, Labiris G, Kozobolis V. Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies. Int Ophthalmol. 2011;31(4):309–19. doi: 10.1007/s10792-011-9460-x.
    1. Kolli S, Aslanides IM. Safety and efficacy of collagen crosslinking for the treatment of keratoconus. Expert Opin Drug Saf. 2010;9(6):949–57. doi: 10.1517/14740338.2010.495117.
    1. Raiskup F, Theuring A, Pillunat LE, Spoerl E. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results. J Cataract Refract Surg. 2015;41(1):41–6.
    1. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008;34(5):796–801. doi: 10.1016/j.jcrs.2007.12.039.
    1. Caporossi A, Mazzotta C, Baiocchi S, Caporossi T, Denaro R, Balestrazzi A. Riboflavin-UVA-induced corneal collagen cross-linking in pediatric patients. Cornea. 2012;31(3):227–31. doi: 10.1097/ICO.0b013e31822159f6.
    1. Chatzis N, Hafezi F. Progression of keratoconus and efficacy of pediatric corneal collagen cross-linking in children and adolescents. J Refract Surg. 2012;28(11):753–8. doi: 10.3928/1081597X-20121011-01.
    1. Vinciguerra R, Rosetta P, Romano MR, Azzolini C, Vinciguerra P. Treatment of refractory infectious keratitis with corneal collagen cross-linking window absorption. Cornea. 2013;32(6):e139–40. doi: 10.1097/ICO.0b013e3182886a8c.
    1. Hafezi F, Iseli HP. Pregnancy-related exacerbation of iatrogenic keratectasia despite corneal collagen crosslinking. J Cataract Refract Surg. 2008;34(7):1219–21. doi: 10.1016/j.jcrs.2008.02.036.
    1. Kohlhaas M, Spoerl E, Speck A, Schilde T, Sandner D, Pillunat LE. A new treatment of keratectasia after LASIK by using collagen with riboflavin/UVA light cross-linking. Klin Monatsbl Augenheilkd. 2005;222(5):430–6. doi: 10.1055/s-2005-857950.
    1. Mackool RJ. Crosslinking for iatrogenic keratectasia after LASIK and for keratoconus. J Cataract Refract Surg. 2008;34(6):879. doi: 10.1016/j.jcrs.2008.02.027.
    1. Salgado JP, Khoramnia R, Lohmann CP. Winkler von Mohrenfels C. Corneal collagen crosslinking in post-LASIK keratectasia. Br J Ophthalmol. 2011;95(4):493–7. doi: 10.1136/bjo.2010.179424.
    1. Schnitzler E, Spörl E, Seiler T. Irradiation of cornea with ultraviolet light and riboflavin administration as a new treatment for erosive corneal processes, preliminary results in four patients. Klin Monbl Augenheilkd. 2000;217(3):190–3. doi: 10.1055/s-2000-10344.
    1. Abbouda A, Estrada AV, Rodriguez AE, Alió JL. Anterior segment optical coherence tomography in evaluation of severe fungal keratitis infections treated by corneal crosslinking. Eur J Ophthalmol. 2014;24(3):320–4. doi: 10.5301/ejo.5000424.
    1. Alio JL, Abbouda A, Valle DD, Del Castillo JM, Fernandez JA. Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. J Ophthalmic Inflamm Infect. 2013;3(1):47. doi: 10.1186/1869-5760-3-47.
    1. Berra M, Galperin G, Boscaro G, Zarate J, Tau J, Chiaradia P, et al. Treatment of Acanthamoeba keratitis by corneal cross-linking. Cornea. 2013;32(2):174–8. doi: 10.1097/ICO.0b013e31825cea99.
    1. del Buey MA, Cristóbal JA, Casas P, Goñi P, Clavel A, Mínguez E, et al. Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates. Am J Ophthalmol. 2012;153(3):399–404. doi: 10.1016/j.ajo.2011.07.025.
    1. Galperin G, Berra M, Tau J, Boscaro G, Zarate J, Berra A. Treatment of fungal keratitis from Fusarium infection by corneal cross-linking. Cornea. 2012;31(2):176–80. doi: 10.1097/ICO.0b013e318221cec7.
    1. Hafezi F, Randleman JB. PACK-CXL: defining CXL for infectious keratitis. J Refract Surg. 2014;30(7):438–9. doi: 10.3928/1081597X-20140609-01.
    1. Hellander-Edman A, Makdoumi K, Mortensen J, Ekesten B. Corneal cross-linking in 9 horses with ulcerative keratitis. BMC Vet Res. 2013;9:128. doi: 10.1186/1746-6148-9-128.
    1. Li Z, Jhanji V, Tao X, Yu H, Chen W, Mu G. Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol. 2013;97(5):669–71. doi: 10.1136/bjophthalmol-2012-302518.
    1. Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010;29(12):1353–8. doi: 10.1097/ICO.0b013e3181d2de91.
    1. Makdoumi K, Mortensen J, Sorkhabi O, Malmvall BE, Crafoord S. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2012;250(1):95–102. doi: 10.1007/s00417-011-1754-1.
    1. Mattila JS, Korsbäck A, Krootila K, Holopainen JM. Treatment of Pseudomonas aeruginosa keratitis with combined corneal cross-linking and human amniotic membrane transplantation. Acta Ophthalmol. 2013;91(5):e410–1. doi: 10.1111/aos.12115.
    1. Müller L, Thiel MA, Kipfer-Kauer AI, Kaufmann C. Corneal cross-linking as supplementary treatment option in melting keratitis: a case series. Klin Monbl Augenheilkd. 2012;229(4):411–5. doi: 10.1055/s-0031-1299420.
    1. Panda A, Krishna SN, Kumar S. Photo-activated riboflavin therapy of refractory corneal ulcers. Cornea. 2012;31(10):1210–3. doi: 10.1097/ICO.0b013e31823f8f48.
    1. Pot SA, Gallhöfer NS, Matheis FL, Voelter-Ratson K, Hafezi F, Spiess BM. Corneal collagen cross-linking as treatment for infectious and noninfectious corneal melting in cats and dogs: results of a prospective, nonrandomized, controlled trial. Vet Ophthalmol. 2014;17(4):250–60. doi: 10.1111/vop.12090.
    1. Pot SA, Gallhöfer NS, Walser-Reinhardt L, Hafezi F, Spiess BM. Treatment of bullous keratopathy with corneal collagen cross-linking in two dogs. Vet Ophthalmol. 2015;18(2):168–73. doi: 10.1111/vop.12137.
    1. Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW., Jr Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012;28(10):706–13. doi: 10.3928/1081597X-20120921-06.
    1. Richoz O, Gatzioufas Z, Hafezi F. Corneal Collagen Cross-Linking for the Treatment of Acanthamoeba Keratitis. Cornea. 2013;32(10) doi: 10.1097/ICO.0b013e31829a689e.
    1. Richoz O, Kling S, Hoogewoud F, Hammer A, Tabibian D, Francois P, et al. Antibacterial efficacy of accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL) J Refract Surg. 2014;30(12):850–4. doi: 10.3928/1081597X-20141118-01.
    1. Sağlk A, Ucakhan OO, Kanpolat A. Ultraviolet A and riboflavin therapy as an adjunct in corneal ulcer refractory to medical treatment. Eye Contact Lens. 2013;39(6):413–5. doi: 10.1097/ICL.0b013e3182960fdf.
    1. Said DG, Elalfy MS, Gatzioufas Z, El-Zakzouk ES, Hassan MA, Saif MY, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 2014;121(7):1377–82. doi: 10.1016/j.ophtha.2014.01.011.
    1. Shetty R, Nagaraja H, Jayadev C, Shivanna Y, Kugar T. Collagen crosslinking in the management of advanced non-resolving microbial keratitis. Br J Ophthalmol. 2014;98(8):1033–5. doi: 10.1136/bjophthalmol-2014-304944.
    1. Sorkhabi R, Sedgipoor M, Mahdavifard A. Collagen cross-linking for resistant corneal ulcer. Int Ophthalmol. 2013;33(1):61–6. doi: 10.1007/s10792-012-9633-2.
    1. Spiess BM, Pot SA, Florin M, Hafezi F. Corneal collagen cross-linking (CXL) for the treatment of melting keratitis in cats and dogs: a pilot study. Vet Ophthalmol. 2014;17(1):1–11. doi: 10.1111/vop.12027.
    1. Tabibian D, Richoz O, Hafezi F. PACK-CXL: Corneal Cross-linking for Treatment of Infectious Keratitis. J Ophthalmic Vis Res. 2015;10(1):77–80. doi: 10.4103/2008-322X.156122.
    1. Tabibian D, Richoz O, Riat A, Schrenzel J, Hafezi F. Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. J Refract Surg. 2014;30(12):855–7. doi: 10.3928/1081597X-20141113-06.
    1. Vazirani J, Vaddavalli PK. Cross-linking for microbial keratitis. Indian J Ophthalmol. 2013;61(8):441–4. doi: 10.4103/0301-4738.116068.
    1. Wong RL, Gangwani RA, Yu LW, Lai JS. New treatments for bacterial keratitis. J Ophthalmol. 2012;2012:831502. doi: 10.1155/2012/831502.
    1. Zhang ZY. Corneal cross-linking for the treatment of fungal keratitis. Cornea. 2013;32(2):217–8. doi: 10.1097/ICO.0b013e3182732d62.
    1. Vajpayee RB, Shafi SN, Maharana PK, Sharma N, Jhanji V. Evaluation of corneal collagen cross-linking as an additional therapy in mycotic keratitis. Clin Experiment Ophthalmol. 2015;43(2):103–7. doi: 10.1111/ceo.12399.
    1. Papaioannou L, Miligkos M, Papathanassiou M. Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis. Cornea. 2015;35(1):62–71. doi: 10.1097/ICO.0000000000000644.
    1. Labiris G, Giarmoukakis A, Larin R, Sideroudi H, Kozobolis VP. Corneal collagen cross-linking in a late-onset graft infectious ulcer: a case report. J Med Case Rep. 2014;8:180. doi: 10.1186/1752-1947-8-180.
    1. Kozobolis V, Labiris G, Gkika M, Sideroudi H, Kaloghianni E, Papadopoulou D, et al. UV-A Collagen Cross-Linking Treatment of Bullous Keratopathy Combined With Corneal Ulcer. Cornea. 2010;29(2):235–8. doi: 10.1097/ICO.0b013e3181a81802.
    1. Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49(8):3402–8. doi: 10.1167/iovs.07-1592.
    1. Naseem I, Ahmad M, Hadi SM. Effect of alkylated and intercalated DNA on the generation of superoxide anion by riboflavin. Biosci Rep. 1988;8(5):485–92. doi: 10.1007/BF01121647.
    1. Pileggi G, Wataha JC, Girard M, Grad I, Schrenzel J, Lange N, et al. Blue light-mediated inactivation of Enterococcus faecalis in vitro. Photodiagnosis Photodyn Ther. 2013;10(2):134–40. doi: 10.1016/j.pdpdt.2012.11.002.
    1. Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965;103(2):360–3. doi: 10.1016/0005-2787(65)90182-6.
    1. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35(1):5–17. doi: 10.1016/j.transci.2006.01.007.
    1. Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21. doi: 10.1562/2003-12-23-RA-036.1.
    1. Wollensak G, Spoerl E, Reber F, Seiler T. Keratocyte cytotoxicity of riboflavin/UVA-treatment in vitro. Eye (Lond) 2004;18(7):718–22. doi: 10.1038/sj.eye.6700751.
    1. Famose F. Evaluation of accelerated collagen cross-linking for the treatment of melting keratitis in ten cats. Vet Ophthalmol. 2015;18(2):95–104. doi: 10.1111/vop.12112.
    1. Famose F. Evaluation of accelerated collagen cross-linking for the treatment of melting keratitis in eight dogs. Vet Ophthalmol. 2014;17(5):358–67. doi: 10.1111/vop.12085.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera